AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27846471 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program consisting of 72 sessions over 9 months
Number of subjects: 152
Study 27846471 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 152
Study 25377872 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 (300 mg single dose)
Number of subjects: 0
Study 25377872 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1278863 (15 mg daily for 14 days)
Number of subjects: 0
Study 25377872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia defined by Cancer Cachexia Study Group (CCSG)
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia defined by CCSG
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional risk
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia (low muscle mass)
Number of subjects: 77
Study 22695408 — intervention group
Group type: EXPERIMENTAL
Intervention: No nutritional risk, malnutrition, or cachexia
Number of subjects: 77
Study 21087072 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted age-specific computerized alert
Number of subjects: 0
Study 21087072 — intervention group
Group type: COMPARATOR
Intervention: Control clinics without alert
Number of subjects: 0
Study 21087072 — intervention group
Group type: COMPARATOR
Intervention: Control clinics after alert activation
Number of subjects: 0
Study 21087072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics after alert activation
Number of subjects: 0
Study 18679152 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected mothers
Number of subjects: 2623
Study 18679152 — intervention group
Group type: COMPARATOR
Intervention: HIV-1-uninfected mothers
Number of subjects: 2623
Study 18679152 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of HIV-1-infected mothers
Number of subjects: 2623
Study 18679152 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with early HIV-1 infection (birth to 4-6 weeks)
Number of subjects: 2623
Study 18679152 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal factors (HIV-1-infected mothers)
Number of subjects: 2623
Study 17136941 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet (GI: 70)
Number of subjects: 7
Study 17136941 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) diet (GI: 35)
Number of subjects: 7
Study 12895690 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya supplement (60 mg total isoflavone equivalents/day)
Number of subjects: 33
Study 12895690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg/day
Number of subjects: 25
Study 10905487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8811149 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mL syringe
Number of subjects: 29
Study 8811149 — intervention group
Group type: COMPARATOR
Intervention: 1-mL syringe
Number of subjects: 29
Study 1577222 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day morning administration of 40 mg famotidine
Number of subjects: 99
Study 1577222 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day bedtime administration of 40 mg famotidine
Number of subjects: 99
Study 1577222 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (morning and bedtime famotidine)
Number of subjects: 99
Study 3919579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral antibiotic prophylaxis
Number of subjects: 86
Study 3919579 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotic prophylaxis
Number of subjects: 86
Study 31444404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 87
Study 31444404 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated women)
Number of subjects: 87
Study 29725951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-perspective-taking manipulation
Number of subjects: 0
Study 29725951 — intervention group
Group type: COMPARATOR
Intervention: Low-perspective-taking manipulation
Number of subjects: 0
Study 25690541 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea dentifrice
Number of subjects: 30
Study 25690541 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-triclosan dentifrice
Number of subjects: 30
Study 24957482 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status-II (FS-II) independence scores at 18 months
Number of subjects: 111
Study 24957482 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on Family (IOF) scales
Number of subjects: 111
Study 24957482 — intervention group
Group type: EXPERIMENTAL
Intervention: General health (GH) scores at 18 months
Number of subjects: 111
Study 24957482 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status-II (FS-II) independence scores association with disability
Number of subjects: 111
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total estradiol levels
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher free estradiol levels
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower testosterone to estradiol ratio
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower total testosterone levels
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower testosterone/estradiol ratio
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower free testosterone levels
Number of subjects: 148
Study 22607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone/estradiol ratio
Number of subjects: 148
Study 20881341 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG plus EMD
Number of subjects: 12
Study 20881341 — intervention group
Group type: COMPARATOR
Intervention: SCTG only
Number of subjects: 12
Study 19020142 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sigmoidectomy with sevoflurane anesthesia
Number of subjects: 0
Study 19020142 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sigmoidectomy with sevoflurane anesthesia
Number of subjects: 0
Study 19020142 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sigmoidectomy with propofol anesthesia
Number of subjects: 0
Study 19020142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoidectomy with propofol anesthesia
Number of subjects: 0
Study 16095427 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume group (MVG)
Number of subjects: 51
Study 16095427 — intervention group
Group type: COMPARATOR
Intervention: Low-volume group (LVG)
Number of subjects: 51
Study 16095427 — intervention group
Group type: COMPARATOR
Intervention: High-volume group (HVG)
Number of subjects: 51
Study 12895219 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 1 g three times daily for 6 months
Number of subjects: 42
Study 12895219 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 2 g three times daily for 6 months
Number of subjects: 42
Study 12895219 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaris 3 g three times daily for 6 months
Number of subjects: 42
Study 12895219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10695778 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 0
Study 10695778 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 0
Study 7587186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral triphasic contraceptives
Number of subjects: 10
Study 7587186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 2030054 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at intensities ranging from 50‐80% VO2max
Number of subjects: 19
Study 2030054 — intervention group
Group type: COMPARATOR
Intervention: Exercise intensity expressed as %VO2max
Number of subjects: 19
Study 2030054 — intervention group
Group type: COMPARATOR
Intervention: Exercise intensity expressed as %OBLA
Number of subjects: 19
Study 6184023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (Group 1, 27 patients)
Number of subjects: 60
Study 6184023 — intervention group
Group type: COMPARATOR
Intervention: hetastarch (Group 2, 33 patients)
Number of subjects: 60
Study 6184023 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (Group 1)
Number of subjects: 60
Study 6184023 — intervention group
Group type: COMPARATOR
Intervention: hetastarch (Group 2)
Number of subjects: 60
Study 31318132 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based peer support groups (ISGs)
Number of subjects: 183
Study 29543887 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously once every 6 months)
Number of subjects: 32
Study 29543887 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (35 mg orally once a week)
Number of subjects: 32
Study 29543887 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Denosumab vs Alendronate
Number of subjects: 32
Study 26917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal bulbar double-cuff (DC) insertion
Number of subjects: 180
Study 26917355 — intervention group
Group type: COMPARATOR
Intervention: Proximal bulbar single-cuff (SC) insertion
Number of subjects: 180
Study 26917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall device explantation
Number of subjects: 180
Study 23114725 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretagogues
Number of subjects: 20
Study 23114725 — intervention group
Group type: COMPARATOR
Intervention: Metformin only (Control)
Number of subjects: 20
Study 21823103 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofield healing
Number of subjects: 76
Study 21823103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock healing
Number of subjects: 76
Study 21823103 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief
Number of subjects: 76
Study 20216324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-tailored cardiac rehabilitation program
Number of subjects: 252
Study 20216324 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient cardiac rehabilitation program
Number of subjects: 252
Study 17439564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236
Study 17439564 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study 15616290 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate at 2,000/125 mg (5 days)
Number of subjects: 893
Study 15616290 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate at 875/125 mg (7 days)
Number of subjects: 893
Study 15616290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 893
Study 12151148 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia group (40 women)
Number of subjects: 71
Study 12151148 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group (31 women)
Number of subjects: 71
Study 12151148 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preeclampsia group
Number of subjects: 71
Study 12151148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparous women with preeclampsia
Number of subjects: 71
Study 10669900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 219
Study 10669900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 8915932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG) 750 mg/kg
Number of subjects: 17
Study 8915932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8915932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIG)
Number of subjects: 17
Study 1872270 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (1,000,000 U intravenous bolus dose), followed by heparin infusion 3 hours later
Number of subjects: 43
Study 1872270 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (10,000 U intravenous bolus, followed by continuous infusion)
Number of subjects: 43
Study 1872270 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (intravenous nitroglycerin, beta blockers and calcium antagonists)
Number of subjects: 43
Study 6358552 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education program
Number of subjects: 0
Study 6358552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse counseling session added to written materials
Number of subjects: 0
Study 6358552 — intervention group
Group type: COMPARATOR
Intervention: Telephone information service
Number of subjects: 0
Study 6358552 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education systems
Number of subjects: 0
Study 31684759 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (1.5 µg/min for 20 minutes)
Number of subjects: 34
Study 31684759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 34
Study 31684759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 34
Study 31684759 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 34
Study 28748706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-integrated pump system with a low glucose threshold suspend feature (SIP+TS)
Number of subjects: 0
Study 28748706 — intervention group
Group type: COMPARATOR
Intervention: Standard metrics of hypoglycemia
Number of subjects: 0
Study 25588971 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) group
Number of subjects: 47
Study 25588971 — intervention group
Group type: COMPARATOR
Intervention: Fibre group
Number of subjects: 47
Study 25074387 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) 20 g
Number of subjects: 17
Study 25074387 — intervention group
Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) 20 g (corn oil)
Number of subjects: 17
Study 25074387 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 17
Study 22736340 — intervention group
Group type: EXPERIMENTAL
Intervention: General inhalational anesthesia (GA group, n = 30)
Number of subjects: 87
Study 22736340 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA group, n = 28)
Number of subjects: 87
Study 22736340 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus sedation with midazolam (SA+S group, n = 29)
Number of subjects: 87
Study 22736340 — intervention group
Group type: COMPARATOR
Intervention: General inhalational anesthesia (GA group)
Number of subjects: 87
Study 22736340 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA group)
Number of subjects: 87
Study 22736340 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia plus sedation with midazolam (SA+S group)
Number of subjects: 87
Study 20015490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 0
Study 20015490 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 0
Study 17514424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping
Number of subjects: 129
Study 17514424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral proton pump inhibitors (PPIs)
Number of subjects: 129
Study 16318813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 100-120 mg BCG plus 100 mg para-aminomethyl benzoic acid (PAMBA)
Number of subjects: 326
Study 16318813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 50-60 mg BCG plus 100 mg PAMBA
Number of subjects: 326
Study 16318813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 100-120 mg BCG plus 2.0 g epsilon-aminocaproic acid (EACA)
Number of subjects: 326
Study 16318813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 50-60 mg BCG plus 2.0 g EACA
Number of subjects: 326
Study 16318813 — intervention group
Group type: COMPARATOR
Intervention: Control group: 100-120 mg BCG
Number of subjects: 326
Study 11942864 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 40 g/L (7.1 mL/kg, i.e. 500 mL per 70 kg)
Number of subjects: 12
Study 11942864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 30 g/L (7.1 mL/kg)
Number of subjects: 12
Study 11942864 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (21.4 mL/kg)
Number of subjects: 12
Study 11435045 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body surface warmer with abducted upper extremities (n=19)
Number of subjects: 48
Study 11435045 — intervention group
Group type: EXPERIMENTAL
Intervention: No upper body surface warmer with abducted upper extremities (n=19)
Number of subjects: 48
Study 11435045 — intervention group
Group type: COMPARATOR
Intervention: No upper body surface warmer with adducted upper extremities (n=10)
Number of subjects: 48
Study 9739798 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding strategy before consuming the prepared meal
Number of subjects: 94
Study 9739798 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition replaced free recall
Number of subjects: 94
Study 9739798 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding strategy
Number of subjects: 94
Study 9739798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no encoding strategy)
Number of subjects: 94
Study 8069885 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm F from sodium fluoride dentifrice
Number of subjects: 12
Study 8069885 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm F from sodium fluoride dentifrice
Number of subjects: 12
Study 8069885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 ppm F from sodium fluoride dentifrice
Number of subjects: 12
Study 8069885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of data from 1 low-caries subject
Number of subjects: 12
Study 2657276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 199
Study 2657276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 235837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight)
Number of subjects: 5
Study 235837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects kept awake
Number of subjects: 5
Study 235837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg body weight) + Bromazepam (0.1 mg/kg body weight) - subjects allowed to sleep
Number of subjects: 5
Study 235837 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 5
Study 372292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylidrin hydrochloride (24 mg daily)
Number of subjects: 60
Study 372292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31714970 — intervention group
Group type: EXPERIMENTAL
Intervention: High Positive End-Expiratory Pressure (PEEP) with recruitment maneuvers
Number of subjects: 0
Study 31714970 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 0
Study 29370333 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus definition of orthostatic hypotension (OH)
Number of subjects: 1094
Study 29370333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical HR definition of orthostatic hypotension
Number of subjects: 1094
Study 25939484 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg
Number of subjects: 180
Study 25939484 — intervention group
Group type: COMPARATOR
Intervention: placebo-adalimumab
Number of subjects: 180
Study 24307620 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG fluorescence
Number of subjects: 68
Study 24307620 — intervention group
Group type: COMPARATOR
Intervention: Blue dye
Number of subjects: 68
Study 22343798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NAC
Number of subjects: 312
Study 22343798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarenal NAC
Number of subjects: 312
Study 22343798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 20840176 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping group intervention
Number of subjects: 247
Study 20840176 — intervention group
Group type: COMPARATOR
Intervention: Support group (control)
Number of subjects: 247
Study 17040589 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-phenylcaine administered for 10 minutes
Number of subjects: 50
Study 17040589 — intervention group
Group type: COMPARATOR
Intervention: Co-phenylcaine administered for 1 minute
Number of subjects: 50
Study 16131292 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnet device (2700 gauss)
Number of subjects: 65
Study 16131292 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (140 gauss)
Number of subjects: 65
Study 11831546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin coadministered with 2 mg everolimus
Number of subjects: 24
Study 11831546 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin coadministered with 2 mg everolimus
Number of subjects: 24
Study 11831546 — intervention group
Group type: COMPARATOR
Intervention: 2 mg everolimus alone
Number of subjects: 24
Study 10086532 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial blood flow pump (Hemopump; HP) as circulatory support
Number of subjects: 32
Study 10086532 — intervention group
Group type: COMPARATOR
Intervention: CPB, aortic cross-clamping, and cardioplegic arrest
Number of subjects: 32
Study 8748680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (S-T)
Number of subjects: 8
Study 8748680 — intervention group
Group type: COMPARATOR
Intervention: Control group (other neurological diseases)
Number of subjects: 8